NCT05934331View on ClinicalTrials.gov

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

July 27, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions
Malignant Neoplasms of Digestive Organs
Interventions
DRUG

LM-302

Q2W/Q3W，Administered intravenously

DRUG

Toripalimab

Q2W/Q3W,Administered intravenously

DRUG

Capecitabine

BID,Oral Administration

DRUG

Tegafur, Gimeracil and Oteracil Potassium Capsules

BID,Oral Administration

DRUG

Nivolumab

Q4W,Administered intravenously

DRUG

Apatinib

QD,Oral Administration

DRUG

Gemcitabine

Q4W,Administered intravenously

Trial Locations (1)

Unknown

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

LaNova Medicines Zhejiang Co., Ltd.

INDUSTRY